Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells

Colloids and Surfaces B: Biointerfaces

Volumn 117, Issue , 2014, Pages 122-127

  Gao, Lei ^a   Liu, Guiyang ^a   Ma, Jianli ^a   Wang, Xiaoqing ^a   Wang, Fang ^a   Wang, Hongwei ^a   Sun, Junzhong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

H460 human lung cancer cells; Multi drug resistance; Nanosuspension; P gp; Paclitaxel

Indexed keywords

CYTOLOGY; CYTOTOXICITY; DRUG PRODUCTS; DRUG THERAPY; ENZYME INHIBITION; RESPIRATORY SYSTEM;

HUMAN LUNG CANCER CELLS; MULTIDRUG RESISTANCE; NANO-SUSPENSIONS; P-GP; PACLITAXEL;

CELLS;

DEXTRO ALPHA TOCOPHERYL POLY(ETHYLENE GLYCOL) 1000 SUCCINATE; MULTIDRUG RESISTANCE PROTEIN; NANOCRYSTAL; PACLITAXEL; SURFACTANT; UNCLASSIFIED DRUG; NANOPARTICLE; SUSPENSION;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG COATING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; HUMAN CELL; IC 50; LD 50; LUNG CANCER; MEAN RESIDENCE TIME; NANOSUSPENSION; NONHUMAN; PRIORITY JOURNAL; SUSPENSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL DEATH; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; IC50; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICE, INBRED BALB C; NANOPARTICLES; P-GLYCOPROTEIN; PACLITAXEL; SURFACE-ACTIVE AGENTS; SUSPENSIONS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896046718     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.02.016     Document Type: Article

References (31)

1. Lou H., Zhang X., Gao L., Feng F., Wang J., Wei X., Yu Z., Zhang D., Zhang Q. Int. J. Pharm. 2009, 379:181.
2. Lou H., Gao L., Wei X., Zhang Z., Zheng D., Zhang D., Zhang X., Li Y., Zhang Q. Coll. Surf. B: Biointerf. 2011, 87:319.
3. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Cancer Treat. Rev. 2008, 34:592.
4. Duhem C., Ries F., Dicato M. Oncologist 1996, 1:151.
5. Teodori E., Dei S., Martelli C., Scapecchi S., Gualtieri F. Curr. Drug Targets 2006, 7:893.
6. Wang C., Guo L.B., Ma J.Y., Li Y.M., Liu H.M. Int. J. Oncol. 2013, 43:1607.
7. Zhao G., Huang J., Xue K., Si L., Li G. Eur. J. Pharm. Sci. 2013, 50:429.
8. Szaflarski W., Sujka-Kordowska P., Januchowski R., Wojtowicz K., Andrzejewska M., Nowicki M., Zabel M. Biomed. Pharmacother. 2013, 67:497.
9. Long Q.Z., Zhou M., Liu X.G., Du Y.F., Fan J.H., Li X., He D.L. Anticancer Drugs. 2013, 24:810.
10. Guo Y., Luo J., Tan S., Otieno B.O., Zhang Z. Eur. J. Pharm. Sci. 2013, 49:175.
11. Rege B.D., Kao J.P., Polli J.E. Eur. J. Pharm. Sci. 2002, 16:237.
12. Werle M., Takeuchi H., Bernkop-Schnürch A. Expert Rev. Clin. Pharmacol. 2008, 1:429.
13. Ikezoe T., Hisatake Y., Takeuchi T., Ohtsuki Y., Yang Y., Said J.W., Taguchi H., Koeffler H.P. Cancer Res. 2004, 64:7426.
14. Mei L., Zhang Z., Zhao L., Huang L., Yang X.L., Tang J., Feng S.S. Adv. Drug Deliv. Rev. 2013, 65:880.
15. Dintaman J.M., Silverman J.A. Pharm. Res. 1999, 16:1550.
16. Mi Y., Liu Y.T., Feng S.S. Biomaterials 2011, 32:4058.
17. Gao L., Liu G., Kang J., Niu M., Wang Z., Wang H., Ma J., Wang X. Coll. Surf. B: Biointerf. 2013, 111:277.
18. Chen S.Y., Hu S.S., Dong Q., Cai J.X., Zhang W.P., Sun J.Y., Wang T.T., Xie J., He H.R., Xing J.F., Lu J., Dong Y.L. Asian Pac. J. Cancer Prev. 2013, 14:6135.
19. Gao L., Liu G., Ma J., Wang X., Zhou L., Li X. J. Control Rel. 2012, 160:418.
20. Tang X.J., Fu Y.H., Meng Q.H., Li L.M., Ying X.Y., Han M., He Q.J., Yang B., Zeng S., Hu Y.Z., Sheng X.X., Gao J.Q. Int. J. Pharm. 2013, 456:243.
21. Wang J., Sun J., Chen Q., Gao Y., Li L., Li H., Leng D., Wang Y., Sun Y., Jing Y., Wang S., He Z. Biomaterials 2012, 33:6877.
22. Krasavage W.J., Terhaar C.J. J. Agric. Food Chem. 1977, 25:273.
23. Bittner B., Guenzi A., Fullhardt P., Zuercher G., Gonzalez R.C., Mountfield R.J. Arzneim. Forsch. Drug Res. 2002, 52:684.
24. Youk H.J., Lee E., Choi M.K., Lee Y.J., Chung J.H., Kim S.H., Lee C.H., Lim S.J. J. Control Rel. 2005, 107:43.
25. Xu P., Yin Q., Shen J., Chen L., Yu H., Zhang Z., Li Y. Int. J. Pharm. 2013, 454:21.
26. Collnot E.M., Baldes C., Schaefer U.F., Edgar K.J., Wempe M.F., Lehr C.M. Mol. Pharm. 2010, 7:642.
27. Hanke U., May K., Rozehnal V., Nagel S., Siegmund W., Weitschies W. Eur. J. Pharm. Biopharm. 2010, 76:260.
28. Saxena V., Hussain M.D. Int. J. Nanomed. 2012, 7:713.
29. Anbharasi V., Cao N., Feng S. J. Biomed. Mater. Res. 2010, 94A:730.
30. Constantinou C., Papas A., Constantinou A.I. Int. J. Cancer 2008, 123:739.
31. Varma M.V.S., Panchagnula R. Eur. J. Pharm. Sci. 2005, 25:445.